Monoclonal antibodies targeting the inhibitory receptors Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1) have emerged out to be potential target in the management of cancer.
Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights:
- Global TIGIT Inhibitor Market Dynamics
- Clinical Approaches to Target TIGIT
- Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Clinical Trials Adverse Events Scenario
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global TIGIT Inhibitor Market Future Outlook
Download Report:
Monoclonal antibodies targeting the inhibitory receptors Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1) have emerged out to be potential target in the management of cancer. However, despite the enormous success of immune checkpoint therapy, several patients do not respond and several develop treatment related adverse events. Therefore, researchers have shown great interest in discovering new immune checkpoints that could be safely targeted across various malignancies.
Recently, T cell immunoglobulin and ITIM domain (TIGIT) has emerged as a particularly attractive target for cancer therapy due to its seemingly central role in limiting anti-tumor responses. The novel immunoreceptor, TIGIT has shown to indirectly suppress T-cell activation and is expressed on multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. Owing to its high expression in cancer cells, researchers developed several anti-TIGIT antibodies as an alternative to manage cancer. The pipeline of novel TIGIT inhibitor is highly crowded and is majorly present in phase-I/II of clinical development.
Among all anti-TIGIT antibodies, Tiragolumab developed by Genentech and Ociperlimab developed by BeiGene are in the most advanced stage of development. Tiragolumab is the first anti-TIGIT therapy which was granted breakthrough therapy designation by US FDA. Tiragolumab works as an immune amplifier, by potentially enhancing the body’s immune response. By binding with TIGIT, Tiragolumab blocks its interaction with poliovirus receptor (PVR or CD155) that can suppress the body’s immune response. The blockade of TIGIT and PD-L1 ma synergistically enable the reactivation of T-cells and enhance NK cell anti-tumor activity. The other drugs in development include Vibostolimab, Domvanalimab, EOS448, COM902, BMS-986207, AGEN307, and several others.
Immunotherapeutic monoclonal antibodies have revolutionized the management of cancer over the past few years by demonstrating superior tolerability and major improvements in long-term survival. However, genomic analyses have revealed that several factors and multiple signaling pathways are involved in the development of cancer and other complex disorders. To enhance the efficacy of the treatment, researchers have also developed their effective counterparts, bispecific antibodies which have the ability to bind to two different antigens simultaneously. The higher binding affinity of bispecific antibody which can bind to more than one epitope led to enhancement in the cytotoxic effects due to direct recruitment of effector cells on the site of the disease. In comparison to monoclonal antibodies, the bispecific have small size and have the ability to pass through blood brain barrier. The novel drug, AGEN1777 is a potentially first in class bispecific anti-TIGIT antibody engineered by Agenus Bioscience.
As per our report findings, the rising prevalence of various cancers such as colorectal, bowel, lung, breast, and prostate cancers among the global population and rising adoption of immunotherapy to treat cancer is boosting the growth of market. The rising awareness regarding the benefits of immunotherapy over traditional therapies is further driving the demand of immunotherapy among cancer patients. The robust response of the therapy has also gained interest of several pharmaceutical giants to actively invest in this sector. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market during the forecast period.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities. The report also estimated the future market opportunity of anti-TIGIT therapy during the forecast period.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366